Skip Nav Destination
Issues
1 February 2007
-
Cover Image
Cover Image
The TP53 tumor suppressor gene is located at 17p13.1. 17p13 allelic losses are very frequent in adrenocortical cancer, and somatic mutations of TP53 are observed in a third of these neoplasms. In malignant adrenocortical tumors, somatic TP53 mutations are associated with p53 accumulation, as determined by immunohistochemistry. The larger figure shows a nuclear staining for p53 in an adrenocortical cancer with a TP53 mutation. By contrast, the smaller figure shows that staining for p53 is not significant in a tumor without TP53 mutation (<1% of cells). For further details, please see Libè et al. on page 844 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorials
The Biology Behind
Molecular Pathways
Human Cancer Biology
Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Tetsuya Okano; Tadashi Kondo; Kiyonaga Fujii; Toshihide Nishimura; Toshimi Takano; Yuichiro Ohe; Koji Tsuta; Yoshihiro Matsuno; Akihiko Gemma; Harbumi Kato; Shoji Kudoh; Setsuo Hirohashi
Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin
Yoichi Tanaka; Masahiro Abe; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Ayako Nakano; Kyoko Takeuchi; Kenichi Kitazoe; Shinsuke Kido; Daisuke Inoue; Keiji Moriyama; Toshihiro Hashimoto; Shuji Ozaki; Toshio Matsumoto
Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity
Rossella Libè; Lionel Groussin; Frédérique Tissier; Caroline Elie; Fernande René-Corail; Amato Fratticci; Eric Jullian; Paolo Beck-Peccoz; Xavier Bertagna; Christine Gicquel; Jérôme Bertherat
Implications of Endocrine Gland–Derived Vascular Endothelial Growth Factor/Prokineticin-1 Signaling in Human Neuroblastoma Progression
Elly S.W. Ngan; Francesco Y.L. Sit; King Liu Lee; Xiaoping Miao; Zhengwei Yuan; Weilin Wang; John M. Nicholls; Kenneth K.Y. Wong; Mercè Garcia-Barcelo; Vincent C.H. Lui; Paul K.H. Tam
Imaging, Diagnosis, Prognosis
Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer
Lukas A. Hefler; Alexander Mustea; Dominique Könsgen; Nicole Concin; Berno Tanner; Reiner Strick; Georg Heinze; Christoph Grimm; Eva Schuster; Clemens Tempfer; Alexander Reinthaller; Robert Zeillinger
Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System
Sabine Riethdorf; Herbert Fritsche; Volkmar Müller; Thomas Rau; Christian Schindlbeck; Brigitte Rack; Wolfgang Janni; Cornelia Coith; Katrin Beck; Fritz Jänicke; Summer Jackson; Terrie Gornet; Massimo Cristofanilli; Klaus Pantel
The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic Performance
Martijn P.M.Q. van Gils; Daphne Hessels; Onno van Hooij; Sander A. Jannink; W. Pim Peelen; Suzanne L.J. Hanssen; J. Alfred Witjes; Erik B. Cornel; Herbert F.M. Karthaus; Geert A.H.J. Smits; Gerhard A. Dijkman; Peter F.A. Mulders; Jack A. Schalken
Cancer Therapy: Clinical
A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy
Deirdre O'Mahony; John C. Morris; Cate Quinn; Wendy Gao; Wyndham H. Wilson; Barry Gause; Stefania Pittaluga; Sattva Neelapu; Margaret Brown; Thomas A. Fleisher; James L. Gulley; Jeffrey Schlom; Robert Nussenblatt; Paul Albert; Thomas A. Davis; Israel Lowy; Mike Petrus; Thomas A. Waldmann; John E. Janik
Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil
Milind M. Javle; Shousong Cao; Farukh A. Durrani; Lakshmi Pendyala; David D. Lawrence; Patrick F. Smith; Patrick J. Creaven; Diane C. Noel; Renuka V. Iyer; Youcef M. Rustum
A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing
Paula M. Fracasso; Howard Burris, III; Matthew A. Arquette; Ramaswamy Govindan; Feng Gao; Lisa P. Wright; Sherry A. Goodner; F. Anthony Greco; Suzanne F. Jones; Noel Willcut; Catherine Chodkiewicz; Amit Pathak; Gregory M. Springett; George R. Simon; Daniel M. Sullivan; Raphaël Marcelpoil; Shelley D. Mayfield; David Mauro; Christopher R. Garrett
Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10
Pascal Sève; Raymond Lai; Keyue Ding; Timothy Winton; Charles Butts; John Mackey; Charles Dumontet; Laith Dabbagh; Sarit Aviel-Ronen; Lesley Seymour; Marlo Whitehead; Ming-Sound Tsao; Frances A. Shepherd; Tony Reiman
Cancer Therapy: Preclinical
Cell Type–Specific, Topoisomerase II–Dependent Inhibition of Hypoxia-Inducible Factor-1α Protein Accumulation by NSC 644221
Mark Creighton-Gutteridge; John H. Cardellina, II; Andrew G. Stephen; Annamaria Rapisarda; Badarch Uranchimeg; Karen Hite; William A. Denny; Robert H. Shoemaker; Giovanni Melillo
Cyclophosphamide-Using Nonmyeloablative Allogeneic Cell Therapy against Renal Cancer with a Reduced Risk of Graft-versus-Host Disease
Masatoshi Eto; Masahiko Harano; Katsunori Tatsugami; Mamoru Harada; Yoriyuki Kamiryo; Keijiro Kiyoshima; Masumitsu Hamaguchi; Masazumi Tsuneyoshi; Yasunobu Yoshikai; Seiji Naito
Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo
Frida Ponthan; Malin Wickström; Helena Gleissman; Ole M. Fuskevåg; Lova Segerström; Baldur Sveinbjörnsson; Christopher P.F. Redfern; Staffan Eksborg; Per Kogner; John I. Johnsen
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.